Shares of MEDBOT-B fell sharply during Friday's intraday session, declining 5.36% as the stock gave back gains following a strong rally in the prior session.

The decline comes after the stock surged over 10% on Thursday, driven by a positive profit warning issued on July 22. The company announced it expects to record its first-ever half-year net profit of RMB 28 million to RMB 40 million for the six months ended June 30, a significant turnaround from a net loss of RMB 115 million in the same period last year. Revenue is projected to jump approximately 200% to 230% year over year, fueled by robust sales of its Toumai laparoscopic surgical robot, with overseas market revenue surging over 450%. Despite these strong fundamentals, profit-taking pressure emerged, compounded by broader weakness in the Health Care Equipment sector and ongoing selling pressure from recently approved full-circulation H-shares.

Market sentiment was further dampened by competitive concerns regarding potential pricing moves from industry leader Intuitive Surgical, contributing to the stock's intraday pullback.